Boston-based Valo Health has entered into a definitive merger agreement with Khosla Ventures Acquisition Co. (KVAC), a special purpose acquisition company or SPAC. The transaction represents a pro forma market value of approximately $2.8 billion for the combined company. Valo anticipates the pro forma cash balance of the combined company will be approximately $750 million before expenses. Founded by Flagship Pioneering, Valo has built an internal pipeline with two […]

Local biotechs have been busy this spring raising funds through highly successful IPOs and funding rounds. Boston-based Talaris Therapeutics’ IPO, which closed on May 11, raised approximately $150 million for the company. Known as Regenerex at its founding in 2002, Talaris, is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic […]

Cambridge-based iTeos Therapeutics and GlaxoSmithKline (GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical […]

Lexington biotech Agenus has granted Bristol Myers Squibb an exclusive global license for its proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies […]

The FDA has granted accelerated approval to Biogen and Eisai  for Aduhelm™ (aducanumab-avwa), a human monoclonal antibody, as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. Biogen licensed Aduhelm from Neurimmune in 2007 under a collaborative development and license agreement. […]